Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma

被引:49
|
作者
Rintala, M [1 ]
Inki, P
Klemi, P
Jalkanen, M
Grénman, S
机构
[1] Univ Turku, Cent Hosp, Dept Obstet & Gynecol, FIN-20520 Turku, Finland
[2] Univ Turku, Cent Hosp, Dept Pathol, FIN-20520 Turku, Finland
[3] Turku Univ, Ctr Biotechnol, Turku, Finland
[4] Abo Akad Univ, Turku, Finland
关键词
syndecan-1; prognosis; clinical outcome; cervical carcinoma;
D O I
10.1006/gyno.1999.5595
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. The expression of syndecan-1, a cell surface heparan sulfate proteoglycan, is reduced during malignant transformation of squamous cells. Studies on squamous cell carcinoma of the head and neck have shown that syndecan-1-positive tumors are associated with longer overall and recurrence-free survival. The purpose of this study was to analyze syndecan-1 expression in invasive cervical carcinoma and to examine the association of syndecan-1 expression with prognostic factors and overall survival. Methods. The study population consisted of 124 patients treated for primary invasive carcinoma of the uterine cervix at the Turku University Central Hospital during the years 1970-1988. The material consisted of 102 (82.3%) squamous cell carcinomas, 16 (12.9%) adenocarcinomas and 1 (0.8%) adenosquamous carcinoma, 1(0.8%) small cell carcinoma, 1 (0.8%) adenoid basal carcinoma, 1 (0.8%) carcinosarcoma, and 2 (1.6%) unclassified cervical carcinomas. Syndecan-1 expression was determined on paraffin-embedded tissue blocks using a human syndecan-1-specific monoclonal antibody B-B4 and immunohistochemistry. The expression of syndecan-1 was classified according to staining intensity as well as the percentage of positively stained tumor cells. Results. Staining intensity was strong in 44 (36%) samples, while 24 (19%) specimens remained syndecan-1-negative. In 49 (40%) samples, the percentage of syndecan-1-positive cells was greater than or equal to 90%. Syndecan-1 expression, as determined by greater than or equal to 50% positively stained tumor cells, was associated with the grade of differentiation (P = 0.03) and squamous histology (P < 0.001), but was not associated with clinical stage (P = 0.16) or disease-free survival (P = 0.86). Age (P = 0.003) and clinical stage (P < 0.001) were significant prognostic factors, but syndecan-1 expression determined neither by percentage of positively stained tumor cells nor by staining intensity was associated with the outcome. Conclusions. In cervical carcinoma syndecan-1 is associated with histological differentiation grade and squamous histology, but does not predict clinical outcome. (C) 1999 Academic Press.
引用
收藏
页码:372 / 378
页数:7
相关论文
共 50 条
  • [21] Significance of Syndecan-1 Expression in Ductal Carcinoma In Situ of the Breast
    Tiemann, Katharina
    Weigel, Marion Tina
    Alkatout, Ibrahim
    Wenners, Antonia Sophie
    Mundhenke, Heidi
    Schaefer, Fritz Werner
    Bauer, Maret
    Schem, Christian
    Maass, Nicolai
    Jonat, Walter
    Mundhenke, Christoph
    ANTICANCER RESEARCH, 2014, 34 (07) : 3607 - 3616
  • [22] Changes in the expression of syndecan-1 in the colorectal adenoma–carcinoma sequence
    R. M. Day
    Xingpei Hao
    Mohammad Ilyas
    Peter Daszak
    Ian C. Talbot
    Alastair Forbes
    Virchows Archiv, 1999, 434 : 121 - 125
  • [23] The Association of Plasma Syndecan-1 and Mortality in Patients With Septic Shock
    Nandi, U.
    Puskarich, M.
    Jones, A.
    ANNALS OF EMERGENCY MEDICINE, 2017, 70 (04) : S24 - S24
  • [24] Shed syndecan-1 translocates to the nucleus of tumor and host cells
    Stewart, Mark
    Ramani, Vishnu
    Sanderson, Ralph
    GLYCOBIOLOGY, 2012, 22 (11) : 1604 - 1604
  • [25] Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma
    Stanley, MJ
    Stanley, MW
    Sanderson, RD
    Zera, R
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1999, 112 (03) : 377 - 383
  • [26] Expression of Syndecan-1 in Papillary Carcinoma of the Thyroid with Extracapsular Invasion
    Bologna-Molina, Ronell
    Gonzalez-Gonzalez, Rogelio
    Mosqueda-Taylor, Adalberto
    Molina-Frechero, Nelly
    Damian-Matsumura, Pablo
    Dominguez-Malagon, Hugo
    ARCHIVES OF MEDICAL RESEARCH, 2010, 41 (01) : 33 - 37
  • [27] Expression of syndecan-1, in thyroid papillary carcinoma with extracapsular invasion
    Bologna, R.
    Gonzalez, R.
    Mosqueda, A.
    Molina, N.
    Dominguez, H.
    ORAL ONCOLOGY, 2009, : 130 - 130
  • [28] Serum and tissue syndecan-1 levels in renal cell carcinoma
    Niedworok, Christian
    Kempkensteffen, Carsten
    Eisenhardt, Andreas
    Tschirdewahn, Stephan
    Rehme, Christian
    Panic, Andrej
    Reis, Henning
    Baba, Hideo
    Nyirady, Peter
    Hadaschik, Boris
    Kovalszky, Ilona
    Szarvas, Tibor
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 (03) : 1167 - 1176
  • [29] Syndecan-1 serves as a marker for the progression of epithelial ovarian carcinoma
    Guo, Q.
    Yang, X.
    Ma, Y.
    Ma, L.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2015, 36 (05) : 506 - 513
  • [30] Expression of syndecan-1 in oral cavity squamous cell carcinoma
    Wozniak, Marta
    Nahajowski, Marek
    Hnitecka, Sylwia
    Rutkowska, Monika
    Nowak, Martyna
    Mitelsztet, Patryk
    Szkudlarek, Danuta
    Makuch, Sebastian
    JOURNAL OF HISTOTECHNOLOGY, 2021, 44 (01) : 46 - 51